Cargando…
Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS
We determined whether the myelofibrosis drug ruxolitinib, an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could interact with the multiple sclerosis drug dimethyl-fumarate (DMF) to kill tumor cells; studies used the in vivo active form of the drug, mono-methyl fumarate (MMF). Ruxolitinib interact...
Autores principales: | Tavallai, Mehrad, Booth, Laurence, Roberts, Jane L., McGuire, William P., Poklepovic, Andrew, Dent, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951212/ https://www.ncbi.nlm.nih.gov/pubmed/26981780 http://dx.doi.org/10.18632/oncotarget.8039 |
Ejemplares similares
-
Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic
por: Tavallai, Mehrad, et al.
Publicado: (2016) -
Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells
por: Tavallai, Mehrad, et al.
Publicado: (2015) -
Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2016) -
Regulation of Bim in Health and Disease
por: Sionov, Ronit Vogt, et al.
Publicado: (2015) -
The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
por: Booth, Laurence, et al.
Publicado: (2016)